Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

MT Newswires03:37

Express News | Arvinas: Vepdegestrant to Be Combined With Pfizer's Cdk4 Inhibitor Atirmociclib in a First-Line Phase 3 Trial Planned to Initiate in 2025

BreakingsJan 10 20:01

Express News | Arvinas Inc - Topline Data From Veritac-2 Phase 3 Trial Expected in 1Q25

BreakingsJan 10 20:00

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials With Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

GlobeNewswireJan 10 20:00

Here Are Morgan Stanley's Key Oncology Catalysts for 2025

Seeking AlphaDec 28, 2024 23:31

Arvinas, Inc.'s (NASDAQ:ARVN) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

Simply Wall StDec 28, 2024 21:04